IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market
IceCure Medical reported preliminary, unaudited estimates indicating U.S. revenue for ProSense systems and cryoprobes grew by more than 30% in the first quarter of 2026 compared to the prior year. The commercial momentum follows the recent inclusion of cryoablation in the American Society of Breast Surgeons Resource Guide as a recommended treatment for low-risk, early-stage breast cancer.
Key figures
- Guidance
- U.S. revenue of ProSense® systems and cryoprobes increased more than 30% in the first quarter of 2026 compared to the same period last year (preliminary, unaudited estimates)
- Revenue Yoy
- more than 30%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.